About Event
The 6th TCR-Based Therapies Summit remains the industry’s only and definitive meeting to conquer the challenges created by T-cell receptor biology, to capitalize on and unlock the inherent advantages of TCRs in solid tumors and beyond. Â
As the field focuses on securing clinical validation, we dove into preclinical and clinical data (*Over 50% talks sharing new data!) from first and next-generation TCR therapies, with peers across discovery, translation, R&D, and clinical development, and turbocharge TCR and target discovery efforts to expand delivery to novel patient populations and indications. Â
What You Missed Out On:
Spearhead discovery of novel target antigens and leverage mass spectrometry to validate their tumor-specificity and expression levels to guarantee patient safety with Pan Cancer T and ALKemist BioÂ
Review and analyze data from clinical trials to affirm efficacy and safety in patients, while uncovering biomarkers for response and target patient populations with Immatics, Obsidian Therapeutics, Marengo Therapeutics, and MedigeneÂ
Unlock TCR discovery across new HLA and epitopes, while leveraging affinity maturation and engineering to optimize TCR molecules for safe and specific targeting with minimal cross-reactivity with BioNTech, Anocca, TScan, Aethon Therapeutics, and 3T BiosciencesÂ
Equip your therapy to exhibit best-in-class infiltration and durability in the solid tumor microenvironment … through bispecific design, engineering with co-receptors and switch receptors, and memory phenotypes with Moonlight Bio, Captain T Cell, T-Knife, Affini-T Therapeutics, and Pan Cancer TÂ
*New for 2025: Discover how developers are moving beyond oncology to apply TCR-based therapies to target and treat autoimmune indications and infectious diseases with Immunocore and GentiBioÂ
Â